Targeted therapies, which block various mediators of inflammation (eg TNF, IL6) or their intracellular signalling pathways (JAK), as well as those which block T-cell activation, or deplete autoantibodies producing B-cells, have revolutionized the treatment of RA: dramatically relieving pain, restoring function, and preventing joint damage and disability; thereby inducing disease remission.